We are pleased to announce a multi-year research collaboration between Alise Pharma and the University of California's Department of Integrative Biology and Physiology. This partnership will focus on investigating novel nutrient combinations for supporting joint health — an area where current supplement options often fall short of the clinical evidence consumers deserve.

Joint discomfort affects an estimated 91 million adults in the United States alone, and the number continues to grow as the population ages. While glucosamine and chondroitin have dominated the joint supplement market for decades, the clinical evidence behind them remains inconsistent. Our collaboration with UC aims to identify and validate new ingredient combinations that address the root biological mechanisms of joint degradation — not just the symptoms.

The Research Goals

The partnership is organized around three primary research objectives. First, we will conduct a systematic evaluation of novel nutrient combinations targeting the inflammatory pathways most closely linked to cartilage breakdown. This includes studying synergistic effects between compounds such as undenatured type II collagen, boswellic acids, methylsulfonylmethane (MSM), and specific polyphenol extracts that have shown promising but incomplete evidence in smaller studies.

Second, the research will examine how these combinations affect the extracellular matrix proteins that give cartilage its structural integrity. Rather than simply suppressing inflammation, we want to understand whether targeted supplementation can support the body's natural cartilage maintenance processes — an approach that could produce longer-lasting benefits compared to conventional anti-inflammatory strategies.

Third, we will explore biomarker-guided dosing strategies. Individual responses to joint supplements vary significantly, and current dosing recommendations are based on population averages. By identifying biomarkers that predict response, we hope to develop protocols that allow healthcare practitioners to personalize joint health regimens for their patients.

Clinical Trial Design

The collaboration will include two clinical trials. The first is a 16-week randomized, double-blind, placebo-controlled trial enrolling approximately 200 participants aged 40 to 70 with mild to moderate joint discomfort. This trial will evaluate the efficacy of our lead nutrient combination against placebo, using validated joint function assessments including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the 6-minute walk test.

The second trial, planned for Year 2 of the partnership, will be a longer 24-week study designed to assess sustained effects and explore dose-response relationships. This trial will also include a biomarker sub-study, collecting blood and synovial fluid samples to measure changes in inflammatory mediators, collagen turnover markers, and oxidative stress indicators.

Both trials will be conducted at UC's clinical research facilities, leveraging their extensive experience in musculoskeletal research and their established participant recruitment infrastructure. All results will be submitted for publication in peer-reviewed journals, regardless of the outcomes — a commitment to transparency that we believe is essential for building trust in the supplement industry.

Why This Partnership Matters

Academic-industry partnerships in the supplement space are relatively uncommon, and that is part of the problem. Too many products reach the market backed by only preclinical data, theoretical mechanisms, or small open-label studies that lack the statistical power to draw meaningful conclusions. By partnering with a top-tier research university, we are holding ourselves to a higher standard of evidence.

The University of California brings world-class expertise in musculoskeletal biology, clinical trial methodology, and biostatistics. Their team, led by Dr. Patricia Hernandez in the Department of Integrative Biology, has published over 80 peer-reviewed papers on joint physiology and cartilage biology. This depth of expertise ensures that our research is designed, executed, and analyzed with the same rigor applied to pharmaceutical drug trials.

Expected Outcomes and Timeline

The first clinical trial is scheduled to begin enrollment in Q2 2026, with preliminary results expected by the end of 2026. The second trial will begin in early 2027, with final data expected by mid-2027. If the results support our hypotheses, we anticipate launching a clinically validated joint health product by late 2027.

Beyond the specific products that may emerge from this research, we expect the partnership to generate valuable insights into joint biology that will inform our broader product development strategy. The biomarker data, in particular, could help us develop companion diagnostics that allow customers to track their progress and adjust their supplementation accordingly.

We will provide regular updates on the progress of this research through our blog and newsletter. Science takes time, and we are committed to doing it right rather than rushing incomplete findings to market.